ValueQ4, 24Q1, 25Q2, 25TTMCash from investing activities3.03 M3.85 M2.66 M5.3 MCash from financing activities-435 K-40 K——Free cash flow-5.94 M-5.54 M-5.65 M-22.01 M
Pluri Inc
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.